TIDMCOS

RNS Number : 4776U

Collagen Solutions PLC

19 January 2017

Collagen Solutions Plc

(the "Company" or the "Group")

Team Strengthened with New Scientific Advisory Board Appointments

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, is announcing the creation of a new Scientific Advisory Board ("SAB") that will advise the Company on opportunities in regenerative medicine.

Commenting on the creation of the Scientific Advisory Board, Jamal Rushdy, CEO of Collagen Solutions said: "We have assembled a highly experienced and dynamic SAB with a combination of significant industry backgrounds and complementary technical and scientific knowledge within the field of regenerative medicine. In addition to providing advice and direction on our current development projects and core business, the SAB will help us to assess future market directions and to guide our activities towards the development of both commercially and clinically relevant, next generation products."

The three appointees are:

Andrew Lynn, PhD:

Dr. Lynn is a successful entrepreneur with experience in early-stage life-sciences and technology companies. He is currently CEO of Fluid Analytics Limited, and was also the founder of Orthomimetics Ltd., which developed ChondroMimetic based on the work for his PhD thesis at the University of Cambridge. He has acted as a close adviser to the Company on the development programme for ChondroMimetic following the Company's acquisition of Orthomimetics assets in September 2015.

Professor William (Bill) Walsh, PhD:

Professor Walsh has over 27 years of academic and industry-related research experience in orthopaedics and other surgical fields. He is currently a Full Professor at the Prince of Wales Clinical School at the University of New South Wales, Australia and Director of the Surgical & Orthopaedic Research Laboratories. Professor Walsh's research interests are in understanding the molecular interactions at the interface between implanted materials and the connective tissues of the body, as it relates to orthopaedic, plastic and reconstructive and vascular surgery. Professor Walsh has extensive practical experience of working with the novel collagen-based products that the Company has developed.

Tom Buckland, PhD:

Dr. Buckland was a co-founder of ApaTech Ltd., Research and Development Director with Baxter Inc., and Managing Director of NuVasive (UK) Ltd. Tom has over 15 years' experience in medical device product development, manufacture, regulatory approval, intellectual property management and commercialisation. He holds several non-executive director positions with start-up companies in the orthopaedic space, in addition to his role as Entrepreneur-in-Residence within the technology transfer group at Imperial Innovations, where he is focused on managing the orthopaedic portfolio and selected medical technologies.

About Collagen Solutions:

Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval.

For additional information, please visit www.collagensolutions.com.

Enquiries:

 
  Collagen Solutions Plc                                            Contact via Walbrook 
 Jamal Rushdy, Chief Executive 
  Officer 
 Gill Black, Chief Financial 
  Officer 
 
 Cenkos Securities plc (Nominated                                     Tel: 0207 397 8900 
  Adviser and Broker) 
  Stephen Keys 
  Steve Cox 
 
 Walbrook PR                               Tel: 020 7933 8780 or collagen@walbrookpr.com 
 Mike Wort                                                            Mob: 07900 608 002 
 Anna Dunphy                                                          Mob: 07876 741 001

This information is provided by RNS

The company news service from the London Stock Exchange

END

UPDGGUGUGUPMGGR

(END) Dow Jones Newswires

January 19, 2017 02:00 ET (07:00 GMT)

Collagen Solutions (LSE:COS)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Collagen Solutions Charts.
Collagen Solutions (LSE:COS)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Collagen Solutions Charts.